On June 30, Xingqi eye medicine (300573) dived all the way after opening low, and its stock price once fell by 20cm. As of press release, Xingqi eye medicine opened the limit, but still fell by more than 19% to 136 yuan / share, with a total market value of 11.2 billion yuan.
On the news side, Xingqi eye medicine has no obvious bad news, but from the recent announcement, the shareholders of Xingqi eye medicine are very busy.
The two shareholders have been reducing their holdings all the way. This time, they have to clear their positions
On the evening of May 17 this year, Xingqi ophthalmic released the announcement of shareholders’ pre disclosure reduction plan. Tongshi Investment Co., Ltd. (hereinafter referred to as “Tongshi investment”), the second shareholder of the company, plans to reduce its holding of no more than 4.4696 million shares within six months after 15 trading days after the announcement, accounting for 5.43% of the total share capital.
Prior to this, Tongshi investment has implemented several rounds of reduction plan. At the end of July 2019, Tongshi investment completed the first round of reduction, with a total reduction of 2.2456 million shares, accounting for 2.72% of the total share capital. From October 2019 to March 2020, Tongshi investment completed the second round of reduction, with a total reduction of 2265700 shares, accounting for 2.75% of the total share capital.
The third round of reduction of Tongshi investment took place from May 29, 2020 to October 15, 2020, with a total reduction of 3.331 million shares, accounting for 4.01% of the total share capital.
This was followed by the fourth round of reduction, which took place from November 5, 2020 to May 14 this year.
From the time of reduction, Tongshi investment’s pace of reduction has not stopped basically, excluding the window period of reduction, it has been basically reducing. It is estimated that Tongshi investment has cashed out about 1.06 billion yuan in the above four rounds of reduction.
And this round of reduction, Tongshi investment simply direct clearance. It is worth mentioning that LAV, the three shareholders, had already completed the liquidation and withdrawal last year, and Liu Jidong, the company’s actual controller, chairman and general manager, also completed a reduction of holdings in November last year, cashing out about 46 million yuan. In addition, the company’s directors and supervisors Gao Ya Nan, Gao E and many other people also implemented the reduction.
Up 40 times since listing
Although shareholders and executives mercilessly sell off, the stock price trend of Xingqi eye medicine is not weak.
Since late March this year, the company’s share price has soared by 96% in 50 trading days, nearly doubling.
From a longer period of time, the performance of Xingqi eye medicine is more eye-catching. Since the listing in 2016, the biggest increase in the company’s share price is more than 40 times, which is a big bull. However, after peaking in August last year, the stock price of Xingqi eye medicine also experienced a deep adjustment, with the maximum withdrawal exceeding 60%. Such a big adjustment is not acceptable to ordinary investors.
The continuous upward trend of stock price is inseparable from the performance behind. Since 2019, the business performance has continued to grow rapidly. In that year, the company realized an operating revenue of 542 million yuan, a year-on-year increase of 25.80%, a net profit of 36 million yuan, and a net profit deducting non recurring profits and losses (hereinafter referred to as deducting non net profit) of 33 million yuan, a year-on-year increase of 162.79% and 208.51%.
In 2020, the company’s business performance will grow again. Its operating income was 689 million yuan, up 26.96% year on year, net profit was 88 million yuan, non net profit was 85 million yuan, up 145.11% and 156.70% year on year.
Before this, many institutions are optimistic
Data show that Xingqi eye medicine focuses on the field of ophthalmic drugs, mainly engaged in the research and development, production and sales of ophthalmic drugs, and its main products are ophthalmic prescription drugs.
Previously, Xingqi eye medicine was sought after by many securities companies. Guosheng securities released Research Report on April 20, saying that it maintained Xingqi eye medicine and bought the rating. The reasons for rating mainly include: 1) the high growth of annual performance meets the expectation, and low concentration of atropine is the main driving force; 2) The R & D of core projects is progressing smoothly; 3) To expand business in East China; 4) Follow up sales of cyclosporine are expected to exceed expectations.
On the same day, Anxin securities also gave Xingqi eyedrops a buying rating. The reasons for rating mainly include: 1) achieving 145% high performance growth in 2020, and the performance growth is in line with market expectations; 2) In 2020, the overall gross profit rate will be 73.13%, and the period expense rate will be 56.74%; 3) Cyclosporine, the core variety, has been successfully listed and its sales volume has been continuously optimistic; 4) Low concentration atropine stage III clinical progress smoothly, the current research and development progress of the world’s leading.